StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
100700.KQ$2230.00-2.39%
Fair $2230.00+0.0%

100700.KQ

Sewoon Medical Co., Ltd

Unknown / UnknownKOSDAQ

$2230.00

-55.00 (-2.39%)

Fairly Valued+0.0%Fair Value $2230.00Fund rank 37/100 · Data gapFallback financials|
SA 45/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $16.1B · quality 78.3/100

Data gap 37/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 77/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

45/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 100700.KQLocal privado en este navegador · Sewoon Medical Co., Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$94.1B

P/E

8.0x

↓

EV/EBITDA

-0.1x

↓

ROE

7.9%

↑

Gross Margin

37.0%

↑

Debt/Equity

0.01

↓
52-Week Range$2230
$2220$3430

TradingView lightweight chart

100700.KQ price, volumen y niveles de valoración

Último $2,250Periodo +158.6%
Fair value: $2,230

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+1.9%

FCF CAGR

+31.2%

FCF margin

25.3%

FCF / Net income

1.35x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $63.66B · net income $11.91B · FCF $16.07B

2022-FY → 2025-FY

Gross margin

37.0%+0.0% pts

Operating margin

20.0%-0.3% pts

Net margin

18.7%+1.4% pts

FCF margin

25.3%+13.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$63.66B$63.66B$60.15B$68.25B$60.12B
Net Income$11.91B$11.91B$12.16B$14.96B$10.41B
EBITDA$18.26B$18.26B$19.14B$22.98B$17.55B
EPS279.00279.00281.00345.00240.00
Gross Margin37.0%37.0%36.9%40.4%37.0%
Operating Margin20.0%20.0%18.9%24.8%20.3%
Net Margin18.7%18.7%20.2%21.9%17.3%
Balance Sheet
Debt/Equity0.010.010.010.010.01
Cash Flow
Free Cash Flow$16.07B$16.07B$11.53B$21.12B$7.11B
Returns
ROE7.9%7.9%8.3%11.1%8.5%
Valuation
P/E7.997.998.868.2512.35
EV/EBITDA-0.06-0.061.192.115.56
P/B0.630.630.740.911.05
Growth & Yield
Revenue Growth5.8%5.8%-11.9%13.5%—
EPS Growth-0.7%-0.7%-18.6%43.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-10.8%

fácil

EPS terminal req.

$197.88

Spread vs growth

10.1%

5Y implied EPS CAGR

-3.0%

fácil

EPS terminal req.

$239.43

Spread vs growth

2.3%

10Y implied EPS CAGR

3.3%

fácil

EPS terminal req.

$385.60

Spread vs growth

-4.0%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -5.5%

Total return

-5.5%

Start / end P/E

8.5x → 8.1x

EPS bridge

281.00 → 279.00

Residual

+0.0%

EPS growth-0.7%
Multiple rerating-4.8%
Dividend+0.0%
Residual / FX / buybacks / cross-term+0.0%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.